

Nomination Committee appointed for the 2021 Annual General Meeting in Oasmia

Uppsala on 20 November 2020 – In accordance with a resolution at Oasmia Pharmaceutical AB's ("Oasmia") Annual General Meeting on 9 September 2020, it is hereby announced that the Nomination Committee for the 2021 Annual General Meeting has been appointed, based on the ownership structure as per 30 September 2020.

The Nomination Committee for the 2021 Annual General Meeting comprises the following members:

- Per Arwidsson, appointed by Arwidssro Investment AB,
- Håkan Lagerberg, appointed by Mastan AB, and
- Anders Härfstrand, Chairman of the Board of Oasmia.

Per Arwidsson has been appointed Chairman of the Nomination Committee.

Oasmia's Annual General Meeting will be held on 27 May 2021.

Shareholders who wish to submit proposals to the Nomination Committee for the 2021 Annual General Meeting may send them by e-mail to nomination@oasmia.com. In order for the Nomination Committee to be able to consider submitted proposals in a constructive manner, these should be submitted well in advance of the Annual General Meeting.

For more information:

Anders Härfstrand, Chairman of the Board of Oasmia

Phone: 018-50 54 40

E-mail: IR@oasmia.com

About Oasmia Pharmaceutical AB

Oasmia is a specialty pharma company dedicated to improving the lives of patients by enhancing the intravenous delivery of established and novel drugs in significant diseases, including cancer. Product development is based on the Company's proprietary drug delivery technology platform XR-17™ which can be applied to medicines used in many therapeutic areas, to develop water soluble formulations of drugs that currently require chemical solubilizers for dissolution. The first product approved using this technology is Apealea® (paclitaxel micellar). Apealea has received market authorization in the European Union and several other territories for the treatment of first relapse in platinum-sensitive ovarian cancer, in combination with carboplatin. The Company is making Apealea accessible to patients through its partnership with Elevar Therapeutics, together with its existing commercial operations in the Nordic region. Oasmia's shares are traded on the Nasdaq Stockholm stock exchange (ticker: OASM). To find out more about Oasmia please visit www.oasmia.com.

Attachments

[Nomination Committee appointed for the 2021 Annual General Meeting in Oasmia](#)
